SCHEMBL16796451

SCHEMBL16796451

CCOC(=O)c1cc(O)n(Cc2cccc(F)c2F)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.44
CYP1A2 P05177 1/20 0.43
THRB P10828 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
POLB P06746 1/20 0.39
P2RY14 Q15391 1/20 0.39
GAA P10253 2/20 0.38
KMT2A Q03164 2/20 0.38
HPGD P15428 1/20 0.38
NR1H2 P55055 1/20 0.38
PTGER1 P34995 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30121985 0.91 TP53 (0.48) TP53CYP1A2THRBSMN1; SMN2NPC1
SCHEMBL15075362 0.91 TP53 (0.48) TP53CYP1A2THRBSMN1; SMN2NPC1
SCHEMBL6068367 0.87 TP53 (0.43) TP53CYP1A2THRBSMN1; SMN2NPC1
SCHEMBL24709394 0.87 ALDH1A1 (0.47) TP53CYP1A2THRBSMN1; SMN2NPC1
SCHEMBL25972034 0.84 P2RY14 (0.39) CYP1A2NPC1RAB9AP2RY14PTGER1
SCHEMBL16796448 0.84 TP53 (0.45) TP53CYP1A2THRBSMN1; SMN2NPC1
SCHEMBL30122290 0.83 TP53 (0.43) TP53CYP1A2THRBSMN1; SMN2NPC1
SCHEMBL16796450 0.83 P2RY14 (0.47) P2RY14KMT2APTGER1MEN1
SCHEMBL16796429 0.82 PTGER1 (0.48) TP53CYP1A2THRBNPC1RAB9A
SCHEMBL23070362 0.82 PTGER1 (0.43) TP53THRBNPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718612-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-08-08 US disclosed
US-11718612-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-08-08 US disclosed
US-20210214364-A1 sGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2021-07-15 US disclosed
US-20210214364-A1 sGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2021-07-15 US disclosed
US-20210094951-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2021-04-01 US disclosed
US-20210094951-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2021-04-01 US disclosed
WO-2021046515-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-03-11 WO disclosed
WO-2021046515-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-03-11 WO disclosed
EP-3092231-B1 SGC STIMULATORS IRONWOOD PHARMACEUTICALS INC (US) 2018-06-27 EP disclosed
EP-3092231-B1 SGC STIMULATORS IRONWOOD PHARMACEUTICALS INC (US) 2018-06-27 EP disclosed
EP-3092231-A1 SGC STIMULATORS Ironwood Pharmaceuticals, Inc. (US) 2016-11-16 EP disclosed
US-20160311826-A1 SGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2016-10-27 US disclosed
US-20160311826-A1 SGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2016-10-27 US disclosed
US-20160311826-A1 SGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2016-10-27 US disclosed
WO-2015089182-A1 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2015-06-18 WO disclosed
WO-2015089182-A1 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2015-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718612-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease RIPK1, RIPK2, RIPK4 TP53 867/4885CYP1A2 4782/4885THRB 1817/4885
US-20210094951-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE RIPK1, RIPK2, RIPK4 TP53 867/4885CYP1A2 4782/4885THRB 1817/4885
US-20160311826-A1 SGC STIMULATORS GUCY1A1, GUCY1B1, GUCY1A2 TP53 4819/4885CYP1A2 2079/4885THRB 2109/4885
US-20210214364-A1 sGC STIMULATORS GUCY1B1, GUCY1A1, GUCY1B2 TP53 4757/4885CYP1A2 1601/4885THRB 1225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.